DBIA
BBH icon

Dumont & Blake Investment Advisors’s VanEck Biotech ETF BBH Stock Holding History

Dumont & Blake Investment Advisors’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,275
Closed -$289K – 177
2015
Q4 		$289K Hold
2,275
– – 0.15% 139
2015
Q3 		$260K Sell
2,275
-80
-3% -$10.6K 0.14% 133
2015
Q2 		$318K Hold
2,355
– – 0.16% 127
2015
Q1 		$305K Hold
2,355
– – 0.15% 125
2014
Q4 		$272K Hold
2,355
– – 0.13% 130
2014
Q3 		$249K Buy
2,355
+160
+7% +$16.2K 0.13% 132
2014
Q2 		$209K Buy
+2,195
New +$197K 0.1% 143

Other funds holding BBH

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LFM
Lumina Fund Management New York $164M AUM 27.72% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return

Dumont & Blake Investment Advisors's BBH Position: Q1 2016 in Review

Dumont & Blake Investment Advisors sold out of VanEck Biotech ETF (BBH) in Q1 2016, closing a stake of 2,275 shares — an estimated $289K sold.

Dumont & Blake Investment Advisors first reported a position in BBH in Q2 2014 and held it in 7 quarters. The position peaked at $318K in Q2 2015. 71 funds tracked by Wall St. Rank hold BBH as of Q1 2016.

  • Dumont & Blake Investment Advisors reported no remaining VanEck Biotech ETF position as of Q1 2016 after selling out during the quarter.
  • Dumont & Blake Investment Advisors sold 2,275 VanEck Biotech ETF shares in Q1 2016, an estimated $289K.
  • Dumont & Blake Investment Advisors first reported a position in VanEck Biotech ETF in Q2 2014 and held it in 7 quarters.
  • Dumont & Blake Investment Advisors's VanEck Biotech ETF position peaked at $318K in Q2 2015.
  • 71 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2016.

Based on Dumont & Blake Investment Advisors's 13F filing for Q1 2016, filed 21 Apr 2016.